GenSight Biologics (GSGTF) Stock Price, News & Analysis

Company Overview

GenSight Biologics S.A. is a France-based biotechnology company focused on developing gene therapies for severe and potentially blinding retinal and optic nerve disorders. The company’s research is based on mitochondrial and optogenetic technologies intended to protect or restore visual function in patients with inherited or degenerative eye diseases.

GenSight’s lead product candidate, LUMEVOQ (GS010), is an investigational gene therapy designed to treat Leber hereditary optic neuropathy, a rare mitochondrial eye disorder that can cause rapid vision loss. The therapy uses an adeno-associated viral vector to deliver a functional version of the mitochondrial ND4 gene. GenSight has also developed GS030, an optogenetic therapy program aimed at restoring light sensitivity in patients with advanced retinal degeneration.

Founded in 2012, GenSight has conducted clinical development activities in Europe and the United States and has worked with ophthalmology researchers and clinical centers internationally. The company’s programs have included clinical trials and regulatory activities related to LUMEVOQ, although the development and regulatory status of its candidates has changed over time.

Key Stats

• Today's Range: $0.08 to $0.08
• 50-Day Range: $0.08 to $0.09
• 52-Week Range: $0.08 to $0.09
• Volume: N/A
• Average Volume: 2,050 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:GSGTF
• CIK: N/A
• Web: www.gensight-biologics.com
• Phone: (317) 621-7220
• Fax: N/A
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A